Med24
diabetes 17. 9. 2026 • 2 min read • U.S. Food and Drug Administration (OpenFDA)

Pilocarpine Hydrochloride Pilocarpine Hydrochloride Pilocarp: FDA Clinical Pharmacology, Indications and Prescribing Update

1 INDICATIONS AND USAGE Pilocarpine hydrochloride ophthalmic solution is indicated for the: Pilocarpine hydrochloride ophthalmic solution is a muscarinic cholinergic agonist indicated for: The reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. (1.1) The...

Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)

Pilocarpine hydrochloride ophthalmic solution is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. It is also utilized for the management of acute angle-closure glaucoma, the prevention of postoperative elevated IOP associated with laser surgery, and the induction of miosis.

Sponsored content

Mechanism of Action and Clinical Data

The mechanism of action involves direct stimulation of muscarinic receptors, causing contraction of the ciliary muscle and opening of the trabecular meshwork, thereby reducing outflow resistance and lowering IOP. Miosis is produced through contraction of the iris sphincter muscle, relieving appositional angle narrowing and closure, particularly in certain types of angle-closure glaucoma. Clinical studies demonstrate a reduction in IOP ranging from 3 mm Hg to 7 mm Hg in patients with open-angle glaucoma. Pharmacokinetic evaluations, conducted in 14 healthy subjects, revealed that pilocarpine concentrations reached steady-state following topical administration, with a mean C max of 3.7 ng/mL and an AUC 0-last value of 7.7 ng×hour/mL on Day 8. The T max values ranged from 0.5 to 1 hour. Dosage involves instilling one drop up to four times daily, typically starting with the 1% concentration for naïve patients. For acute angle-closure glaucoma, treatment with secretory suppressants and hyperosmotic agents may precede pilocarpine use to lower IOP. Initial management involves topical application of 1% or 2% solution up to three times over a 30-minute period, potentially followed by laser iridoplasty or iridomy with a 4% solution prior to the procedure.

Original Scientific Source
U.S. Food and Drug Administration (OpenFDA)
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Advertisement